Evogene Ltd. filings document a foreign private issuer whose disclosures are centered on computational chemistry, ChemPass AI™, and small-molecule product development for pharmaceutical and agricultural markets. Form 6-K reports furnish quarterly and annual financial results, unaudited consolidated financial statements, operating and financial review materials, and presentations incorporated by reference into registration statements.
The filing record also covers material agreements and corporate events tied to Evogene's subsidiaries and platform strategy, including Biomica's BMC128 licensing disclosure, management changes, Nasdaq minimum-bid-price correspondence, and capital-structure disclosures through Form F-3 and Form S-8 references. These documents describe governance and financing context for EVGN ordinary shares and the company's operating subsidiaries.
Evogene Ltd. (EVGN) said Nir Nimrodi, chairman of its board, notified the board on November 13, 2026, that he was resigning as a director and chairman. The company said his resignation was not related to any disagreement about its operations, policies or practices.
Evogene Ltd. (EVGN) held a special general meeting on November 10, 2026, where shareholders approved Proposals Nos. 1–3 by the requisite vote. Shareholders also approved a Cooperation Agreement between L.I.A. Pure Capital Ltd. and Invest-Pro Shukai Hon Ltd., on one hand, and Evogene on the other; the agreement became effective at the end of the meeting. The board comprises Nir Nimrodi, Leon Y. Recanati, Dr. Adi Zuluf-Shani, Oz Adler, Itai Maroz, Shahar Zadok, and Ofer Haviv, the company's President and CEO.
Evogene Ltd. (EVGN) announced acute graft-versus-host disease (aGVHD) as the target indication for its internal AI-driven drug-discovery program, which aims to develop a potential first-in-class small-molecule therapy for patients whose disease does not respond to steroids after hematopoietic stem cell transplantation. Evogene says it has begun generating a diverse series of novel, patentable candidates in several months, featuring new chemical scaffolds, high potency at nanomolar concentrations, target selectivity, and favorable ADME and toxicology profiles.
Using its ChemPass AI™ platform, the program explored more than 110 billion molecules; Evogene is advancing its lead series toward IND-enabling studies. The program is guided by Dr. Corey Cutler, Director of the Adult Stem Cell Transplantation Program at Dana-Farber Cancer Institute, and Prof. Dr. Robert Zeiser, Head of Tumor Immunology at University Medical Center Freiburg. Chief Development Officer Dr. Gabi Tarcic said the program reflects Evogene’s strategy to develop proprietary internal therapeutic assets.
Evogene Ltd. (EVGN) is identified as the issuer in a Form 3 naming Oz Adler as a director.
Evogene Ltd. disclosed an October 6, 2026 Cooperation Agreement with L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd. Dr. Yael Margolin and Mr. Yoshinori Oikawa resigned before signing; the board appointed Dr. Adi Zuluf-Shani and Mr. Oz Adler until a shareholder meeting, where they will stand for election. The meeting will also consider the agreement and elections of Mr. Itay Maroz and Mr. Shahar Zadok to replace Mr. Dan Falk and Dr. Adrian Percy.
After shareholder approval, the board is expected to have seven directors: four reporting-person nominees and three continuing directors expected to serve up to six months. The reporting persons agreed to withdraw their announced tender-offer intention and, subject to the agreement, not commence a special tender offer for 60 days. Evogene agreed during that period not to issue ordinary shares or convertible or exchangeable securities, except employee issuances in the ordinary course consistent with past practice. Shared voting power is reported over 3,057,488 shares (16.94%).
Evogene Ltd. entered into a cooperation agreement with L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd. on October 6, 2026, to resolve outstanding differences and set board and governance arrangements. Shareholders will consider it at a special meeting on November 10, 2026; most provisions require shareholder approval, while the initial director appointments and meeting-convening provisions are excluded from that condition.
Proposals cover approval of the agreement and election of Oz Adler and Dr. Adi Zuloff-Shani as initial shareholder directors; if the agreement is approved, shareholders will also vote on Itay Maroz and Shahar Zadok as additional shareholder directors, replacing Dan Falk and Dr. Adrian Percy. If the approvals and elections pass, the board would include three continuing directors, the two initial directors and the two additional directors. The continuing directors are expected to remain for a transition period currently expected to be up to six months, unless otherwise agreed by the board in consultation with the shareholders. For 60 days after the effective date, the shareholder entities agreed not to commence a special tender offer, while Evogene agreed not to issue ordinary shares or convertible securities except for employee issuances in the ordinary course and in line with prior business practice. The shareholders retain the right to acquire additional shares.
Evogene Ltd. (EVGN) granted director Leon Recanati 2,500 stock options on September 4, 2026, with an exercise price of $0.58 per ordinary share. The options were granted under Evogene's 2021 Share Incentive Plan and vest quarterly at 25% per quarter beginning September 4, 2026, becoming fully vested September 4, 2027. They expire September 4, 2036. A separate informational holding entry lists 1,343,886 ordinary shares held directly.
Evogene Ltd. director Nir Nimrodi received 10,000 stock options on September 4, 2026, under the company’s 2021 Share Incentive Plan. The options have an exercise price of NIS 1.75 per share, equivalent to $0.58 per share, vest 25% per quarter beginning on the grant date, become fully vested by September 4, 2027, and expire September 4, 2036.
The filing also lists existing direct options covering 5,625 ordinary shares at an $11.00 exercise price, expiring April 20, 2030; 1,800 shares each at $10.20, $6.40 and $6.60, expiring September 15, 2032, May 11, 2033 and June 15, 2034; and 10,000 shares at $1.29, expiring August 18, 2035.
Evogene Ltd. (EVGN) director Adrian John Percy received a grant of 2,500 stock options on September 4, 2026, under the 2021 Share Incentive Plan. The options have a $0.58-per-share exercise price and vest 25% per quarter beginning on the grant date, becoming fully vested by September 4, 2027; they expire September 4, 2036. Separately, reported direct options include 1,000 underlying shares at $25.60, expiring December 23, 2028, and 2,500 at $1.29, expiring August 18, 2035.